103177-37-3 Usage
Asthma drugs
Pranlukast is a common respiratory drug, it belongs to asthma drugs , it is the cysteinyl leukotrienes (LTs) receptor antagonist and it can bind to LTC4, LTD4, LTE4 receptors selectively to antagonize their effect . Roles and application are similar to zafirlukast. It is clinically used for the prevention of bronchial asthma. Oral 225mg once, 2 times one day, morning and evening after meal. After taking ,there may be gastrointestinal reactions,or there may be nausea, vomiting, abdominal pain, diarrhea or constipation, sometimes , fever, rash, pruritus and liver function abnormalities such as serum aminotransferase or bilirubin increase are visible . Pregnant women should use with caution , the elderly should take appropriate reductions. This product can not alleviate the onset of asthma.
At present, three leukotriene receptor antagonists are used for the following purposes:
1, zafirlukast :it is effective for mild to moderate asthma ,it can cause improvement in dose-dependent lung function, and reduce the amount of β agonists. Absorption of the product is affected by food, it should not be taken together with food. Oral each 20mg, 2 times/d.
2, montelukast: it is valid for intermittent or persistent asthma in adults and children. This product is approved by the FDA for the treatment of children aged 6 to 12. Absorption of the product is not affected by food, it can be taken with food . Oral each 10mg, once/d.
3, pranlukast :it is used for mild to moderate asthma, pranlukast can increase patients maximum expiratory flow,and improve asthma symptoms, it can be used as a daily treatment of chronic asthma. Each oral 450mg, 2 times/d.
The above information is edited by the lookchem of Tian Ye.
Description
Pranlukast, a novel chromone derivative, was introduced in Japan for
the treatment of bronchial asthma and allergic diseases. Pranlukast is a highly potent,
selective and competitive antagonist of peptidoleukotrienes with high affinity for the
LTD4 receptor. In patients with bronchial asthma, pranlukast was reported to induce
significant improvement in both immediate and late asthmatic response induced by
antigen. Pranlukast is also being evaluated clinically for the treatment of perennial
allergic rhinitis, pediatric asthma, and cutaneous pruritus in dialysis patients. The
therapeutic potential of pranlukast in managing irritable bowel syndrome has been
suggested.
Chemical Properties
Off-white solid
Originator
Ono (Japan)
Uses
Different sources of media describe the Uses of 103177-37-3 differently. You can refer to the following data:
1. A potent, selective and orally active CysLT receptor antagonist. Leukotriene antagonist. Used as an antiasthmatic
2. antiasthmatic;leukotriene receptor-1 antagonist
3. Labeled Pranlukast, intended for use as an internal standard for the quantification of Pranlukast by GC- or LC-mass spectrometry.
Brand name
Onon
Biological Activity
Selective cysteinyl leukotriene receptor 1 (CysLT 1 ) antagonist (IC 50 values are ~ 4-7 and 3620 nM for CysLT 1 and CysLT 2 respectively). Inhibits contraction of airway smooth muscle, microvascular leakage into airways and eosinophil infiltration. Can decrease symptoms of bronchial asthma.
References
1) Nakai?et al. (1988),?New Potent Antagonists of Leukotrienes C4 and D4. 1. Synthesis and Structure-Activity Relationships; J. Med. Chem.?31?84
2) Taniguchi?et al.?(1993),?The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects; J. Allergy Clin. Immunol.?92?507
3) Ciana?et al.?(2006),?The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor; EMBO J.?25?4615
4) Hennen?et al. (2013),?Decoding Signaling and Function of the Orphan G Protein-Coupled Receptor GPR17 with a Small-Molecule Agonist; Sci. Signal.?6?ra93
Check Digit Verification of cas no
The CAS Registry Mumber 103177-37-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,1,7 and 7 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 103177-37:
(8*1)+(7*0)+(6*3)+(5*1)+(4*7)+(3*7)+(2*3)+(1*7)=93
93 % 10 = 3
So 103177-37-3 is a valid CAS Registry Number.
InChI:InChI=1/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
103177-37-3Relevant articles and documents
A direct and high yielding route to 2-(5-tetrazolyl) substituted benzopyran-4-ones: Synthesis of pranlukast
Geen, Graham R.,Giles, Robert G.,Grinter, Trevor J.,Hayler, John D.,Howie, Simon L. B.,Johnson, Graham,Mann, Inderjit S.,Novack, Vance J.,Oxley, Paul W.,Quick, John K.,Smith, Neil
, p. 1065 - 1073 (1997)
A direct and high yielding route to 2-(5-tetrazolyl)benzopyran-4-ones 1, including pranlukast 1a is described. This involves the Claisen condensation reaction between the relevant hydroxyacetophenone 2 and the ethyl ester of tetrazole-2-carboxylic acid 5 to give the 1,3-diketone 6, which is then cyclised to give the desired benzopyran-4-ones 1.
Preparation method for pranlukast
-
, (2019/01/08)
The invention belongs to the field of medicines and especially relates to a preparation method for pranlukast. The method comprises the following steps: A) adding 4-bromobenzoic acid and thionyl chloride into a solvent and reacting, thereby acquiring 4-bromo-benzoyl chloride; B) adding the 4-bromo-benzoyl chloride acquired in the step A), alkali and 3-amino-2-ethyl iodobenzoate into the solvent and reacting, thereby acquiring 2-iodine-3-(4-bromobenzamide) ethyl benzoate; C) adding the 2-iodine-3-(4-bromobenzamide) ethyl benzoate acquired in the step B), alkali and 1-(1H-tetrazole-5-group) aceton into the solvent and reacting, thereby acquiring 4-bromine-N-(4-oxo-2-(1H-tetrazole-5-group)-4H-benzopyrone-8-group) benzamide; D) adding the 4-bromine-N-(4-oxo-2-(1H-tetrazole-5-group)-4H-benzopyrone-8-group) benzamide acquired in the step C), catalyst and alkali into the solvent and reacting, thereby acquiring the product. The method provided by the invention is simple and practicable in process, low in production cost and high in yield.
New preparation method of Pranlukast
-
, (2017/05/27)
The invention provides a new preparation method of drug Pranlukast for treating asthma. The new preparation method includes the specific steps that with 2-aminophenol-4-sulfonic acid as a starting material, a key intermediate 3-amino-2-hydroxyacetophenone is prepared by means of acylation, Fries rearrangement and deprotection, then reacts with 4-(phenylbutoxy)benzoic acid, and then is subjected to condensation with ethyl 1H-tetrazole-5-acetate, and finally preparation is achieved through ring closing under the acidic condition. Compared with the prior art, the raw material used for the new preparation method is low in price and easy to obtain, industrialization of a process can be achieved easily, and the obtained final product is high in purity; and no dangerous process exists, equipment is simple, and the route is novel.